WO2005051933A1 - An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby - Google Patents

An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby Download PDF

Info

Publication number
WO2005051933A1
WO2005051933A1 PCT/IB2004/003829 IB2004003829W WO2005051933A1 WO 2005051933 A1 WO2005051933 A1 WO 2005051933A1 IB 2004003829 W IB2004003829 W IB 2004003829W WO 2005051933 A1 WO2005051933 A1 WO 2005051933A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
alkyl
piperazine
carboxylic acid
Prior art date
Application number
PCT/IB2004/003829
Other languages
French (fr)
Inventor
Yatendra Kumar
Vijay Kumar Kaul
Nitu Singh
Gyan Chand Yadav
Original Assignee
Ranbaxy Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IN1499DE2003 priority Critical
Priority to IN1499/DEL/2003 priority
Application filed by Ranbaxy Laboratories Limited filed Critical Ranbaxy Laboratories Limited
Publication of WO2005051933A1 publication Critical patent/WO2005051933A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18Oxygen atoms
    • C07D263/20Oxygen atoms attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2.] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid

Abstract

Provided herein are process for the synthesis of the 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, which is a key intermediate in the synthesis of oxazolidinone compounds having antibacterial activity. Also provided herein are processes for preparing oxazolidinone compounds. In addition, compounds prepared by the processes provided herein are also encompassed. Formula (I) and Formula (II).

Description

AN IMPROVED PROCESS FOR THE SYNTHESIS OF 4- (4-BENZYL0XY-CARB0NYLAMIN0-2-FLU0R0PH ENYD -PIPΞRAZINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, A KEY INTERMEDIATE FOR OXAZOLIDINONE ANTIMICROBIALS AND COMPOUNDS PREPARED THEREBY
Field of the Invention The present invention relates to processes for the synthesis of the 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I,
Figure imgf000002_0001
Formula I which is a key intermediate in the synthesis of oxazolidinone compounds having antibacterial 10 activity.
Background of the Invention
Oxazolidinones are a new class of synthetic antimicrobial agents, which kill gram- positive pathogens by inhibiting a very early stage of protein synthesis. Oxazolidinones inhibit the formation of ribosomal initiation complex involving 30S and 50S ribosomes 15 leading to prevention of initiation complex formation. Due to their novel mechanism of action, these compounds are active against pathogens resistant to other clinically useful antibiotics. For example, phenyloxazolodinones and phenyl piperazinyl oxazolidinones have been disclosed as being useful antimicrobial agents effective against human and veterinary pathogens including gram positive and acid-fast organisms. 0 A previosly known general method for the synthesis of the intermediate 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I has been reported, which comprises reacting piperazine with l,2-difluoro-4- nitrobenzene in acetonitrile to form l-(2-fluoro-4-nitrophenyl)-piρerazine, which is reacted further with di-tert-butoxycarbonyl anhydride in tetrahydrofuran to form 4-(2-fluoro-4- 5 nitrophenyl) piperazin-l-carboxylic acid tert-butyl ester. The resulting nitro compound is reduced with palladium on carbon in methanol and reacted with benzylchloroformate in tetrahydrofuran to form 4-(4-benzyloxycarbonyl amino-2-fluorophenyl)-piperazin-l- carboxylic acid tert-butyl ester of Formula I.
Available methods for the synthesis of compounds of Formula I suffer from a number of limitations and accordingly, are not suitable for commercial production. For example, known methods require the use of acetonitrile, which is highly toxic, inflammable and difficult to handle at commercial scales; and tetrahydrofuran, which is unsafe and burdened with the risk of explosion and fire due to peroxide formation, as well as being an expensive solvent and adds significant factor in the overall cost of preparation of final product. Further, the nitro group reduction is carried out in methanol and tetrahydrofuran and in the presence of ammonium formate-Pd/C catalyst, which is a highly exothermic reaction. This sudden rise in temperature increases the formation of by-products and thereby decreases the overall product yield. In addition, purification of the compound involves column chromatography, which is cumbersome, tedious and not practicable on an industrial scale; the synthesis of the pure compound involves more steps; and the overall yield of the pure compound is poor. Accordingly, there remains a need for an improved, commercially viable process to synthesize oxazolidinones. Summary of the Invention
The process provided herein encompass novel methods for the synthesis of the 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I, which provides improvements over prior methods of synthesis. In one aspect, there is provided a process for the synthesis of highly pure 4-(4- benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-l-carboxylic acid tert-butyl ester of Formula I,
Figure imgf000003_0001
Formula I comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form l-(2-fluoro-4-nitro-phenyl)- piperazine of Formula II,
Figure imgf000004_0001
contacting the compound of Formula II with di-tert-butoxycarbonyl anhydride to form 4- (2- fluoro-4-nitrophenyl)-piperazine 1-carboxylic acid tert-butyl ester of Formula III,
Figure imgf000004_0002
reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin-l- carboxylic acid tert-butyl ester of Formula IV,
Figure imgf000004_0003
Formula IV and reacting the compound of Formula IN with benzylchloroformate to form 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine- 1-carboxylic acid tert-butyl ester of Formula I. In one aspect, the step of condensing piperazine with l,2-difluoro-4-nitrobenzene is carried out in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof, and at a temperature of, for example, about 40 °C to about 90 °C, or from about 80 °C to about 90 °C.
In another aspect, the step of contacting the compound of Formula II with di-tert- butoxycarbonyl anhydride is carried out in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof.
In yet another aspect, the step of reducing the compound of Formula III is carried out in the presence of a reducing agent, such as palladium on carbon, and in an aromatic hydrocarbon, such as toluene, xylene and the like, or mixtures thereof. In another aspect, the reaction of the compound of Formula IN with benzylchloroformate is carried out in the presence of an inorganic base, such as sodium bicarbonate, potassium carbonate or potassium bicarbonate, in an organic solvent, such as toluene, and at a temperature of about 20 °C to about 40 °C. Processes provided herein are advantageous over prior methods because, among other reasons, involve fewer steps, as some steps are carried out in situ; the purification of compound need not involve column chromatography, which thus makes the processes convenient to operate at commercial scale; the reduction may be carried out in toluene in the presence of Pd/C, avoiding the exothermicity of the reaction and by-product formation; and the processes need not involve the use of tetrahydrofuran, a material associated with a high risk of fire and explosion. Oxazolidinone compounds can be prepared from compounds of Formula I using, for example, using methods disclosed in U.S. Patent No. 6,734,307 and PCT Publication Nos. WO 02/06278, WO 03/007870, WO 03/097059, WO04/089944 and WO04/14392, which are incorporated herein by reference. Scheme I below shows a synthetic route starting from a compound of Formula I to oxazolidinone compounds.
Figure imgf000006_0001
Formula lb
Figure imgf000006_0002
Formula lc
Figure imgf000006_0003
Formula Id Scheme I A compound of Formula I
Figure imgf000007_0001
Formula I can be reacted with a base, e.g., butyl lithium, and glycidyl butyrate to form a compound of
Formula la.
Figure imgf000007_0002
Formula la
The compound of Formula la can be reacted with methane sulphonyl chloride, followed by ammonium hydroxide, and finally acetyl halide of Formula CH3CO-hal (wherein hal is Br, CI or I) to form a compound of Formula lb.
Figure imgf000007_0003
Formula lb
The compound of Formula lb can be deprotected to form a compound of Formula Ic.
Figure imgf000007_0004
The compound of Formula Ic can be reacted with R-T-(W)0-ι-R12 to form a compound of Formula Id
Figure imgf000008_0001
Formula Id wherein T can be a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring can have at least one heteroatom selected from oxygen, nitrogen and sulfur. Preferred forms of T can be aryl and five-membered heteroaryl, which can be further substituted by a group represented by R, wherein R can be H, CHO, (Cι-C6)-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(RδR7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-ORιo, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (C Ci^-alkyl substituted with one or more of F, CI, Br, I, OR4 or SR4, wherein R5 can be H, optionally substituted (C1-C1 )-alkyl, (C3-Cι2)-cycloalkyl, aryl, heteroaryl, ( -C^-alkoxy, or (C1-C6)-alkyl substituted with one or more of F, CI, Br, I or OH; R6 and R7 can be independently selected from H, optionally substituted (CVC1 )-alkyl, (C3-C12)-cycloalkyl, or ( -C^-alkoxy; R8 and R9 can be independently selected from H, (Cι-C6)-alkyl, F, CI, Br, (C1-C12)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R7) wherein R5, Re and R7 can be the same as defined earlier, R10 is H, optionally substituted ( -Cn)- alkyl, (C3-C12)-cycloalkyl, (C!-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; W can be selected from CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(Rι ι)CH2-, -CH2(Rn)N-, CH(Rπ), S, CH2(CO), NH, wherein Rπ can be optionally substituted (C1-C12)-alkyl, (C3-C12)-cycloalkyl, (Cι-C6)- alkoxy, ( -C^-alkyl, aryl or heteroaryl; and R12 can be a suitable leaving group well known to one of ordinary skill in the art, for example, fluoro, chloro, bromo, SCH3, -SO2CH3, -SO2CF3 or OC6H5 and the like. Another aspect encompasses compounds prepared by processes provided herein. Detailed Description of the Invention
In the following section preferred embodiments are described in a way to illustrate the disclosure. However, this does not limit the scope of the present invention.
EXAMPLE Preparation of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl -piperazine- 1 - carboxylic acid tert-butyl ester of Formula I
Piperazine (0.77 mol, 66.2 g) was mixed with toluene (500 mL) and stirred at room temperature and subsequently stirred at 50 °C until a homogenous solution was obtained. 1,2- difluoro-4-nitrobenzene (0.314 mol, 50 g) was added to the piperazine/toluene solution and the reaction mixture was stirred at 80-90 °C for 3-6 hours. The reaction mixture then was cooled to 40-45 °C and diluted with deionized water. The organic layer was separated and about 250-350 mL of toluene was evaporated off under reduced pressure at 40 °C. Di-tert- butoxycarbonyl anhydride (0.334mol, 75 g) was then added dropwise to the reaction mixture at room temperature. The resulting reaction mixture was stirred at room temperature for 1-2 hours and then further diluted with hexane (200 mL) and stirred for 15-20 minutes at room temperature. The solid product formed in the reaction mixture was filtered, washed with hexane (150 mL), and dried under reduced pressure at 60-70°C to yield 4-(2-fluoro-4- nitrophenyl)-piperazine- 1-carboxylic acid tert butyl ester of Formula III. Yield = 1.8-1.9 (w\w); Purity = 96-98% by HPLC.
The compound of Formula III (0.246 mol, 80 g) was added to toluene (800 mL) followed by the addition of palladium on carbon (4 g) at room temperature with continuous stirring. Hydrogen gas was bubbled into the resulting reaction mixture at a pressure of 72 psi. The reaction mixture was stirred for 12-16 hours and then diluted with toluene (150 mL). The reaction mixture was filtered through a celite pad and washed with toluene (200 mL). Sodium bicarbonate solution was added to the reaction mixture at room temperature with continuous stirring. Benzyl chloroformate (0.310 mol, 103 g) was added dropwise to the reaction mixture with continuous stirring for 2-3 hours. Ethyl acetate (1600 mL) was added to the reaction mixture and stirred for about 30 minutes followed by addition of deionized water (400 mL). The organic layer was separated and the solvent was removed under reduced pressure. The semi-solid product was washed with hexane (350 mL) to obtain 4-(4-benzyloxy- carbonylamino-2-fluorophenyl)-piperazine- 1-carboxylic acid tert-butyl ester of Formula I as a solid. Yield = 1.16-1.23 (w/w); Purity = 97-99% by HPLC.

Claims

We Claim: A process for the preparation of 4-(4-benzyloxy-carbonylamino-2- fluorophenyl)-piperazin- 1 -carboxylic acid tert butyl ester of Formula I,
Figure imgf000011_0001
Formula I comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro-4- nitropheyι)-piperazine of Formula II,
Figure imgf000011_0002
Formula II contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2- fluoro-4-nitrophenyl)-piperazine- 1 -carboxylic acid butyl ester of Formula III,
Figure imgf000011_0003
reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin- 1- carboxylic acid tert-butyl ester of Formula IV,
Figure imgf000011_0004
and reacting the compound of Formula TV with benzylchloroformate to form a compound 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazin- 1 -carboxylic acid tert butyl ester of Formula I. 2. The process of claim 1, wherein the reaction of piperazine with l,
2-difluoro-4- nitrobenzene to form Formula II is earned out in an aromatic hydrocarbon.
3. The process of claim 2, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
4. The process of claim 2, wherein the aromatic hydrocarbon is toluene.
5. The process of claim 1, wherein the reaction of piperazine with l,2-difluoro-4- nitrobenzene is carried out at a temperature of about 40 °C to about 90 °C.
6. The process of claim 5, wherein the reaction of piperazine with l,2-difluoro-4- nitrobenzene is carried out at a temperature of about 80 °C to about 90 °C.
7. The process of claim 1 , wherein the reaction of a compound of Formula II with di-tert-butoxycarbonyl anhydride to form a compound of Formula III is carried out in an aromatic hydrocarbon.
8. The process of claim 7, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
9. The process of claim 8, wherein the aromatic hydrocarbon is toluene.
10. The process of claim 1 , wherein the reduction of a compound of Formula III to form a compound of Formula TV is carried out in an aromatic hydrocarbon.
11. The process of claim 10, wherein the aromatic hydrocarbon is selected from toluene, xylene, and mixtures thereof.
12. The process of claim 11, wherein the aromatic hydrocarbon is toluene.
13. The process of claim 1 wherein the reduction of a compound of Formula III to form a compound of Formula TV is carried out in the presence of a reducing agent.
14. The process of claim 13, wherein the reducing agent is palladium on carbon.
15. The process of claim 1 , wherein the reaction of a compound of Formula IV with benzylchloroformate to form a compound of Formula I is carried out in an organic solvent.
16. The process of claim 15, wherein the organic solvent is toluene.
17. The process of claim 1 , wherein the reaction of a compound of Formula IV with benzylchloroformate is carried out in the presence of an inorganic base.
18. The process of claim 17, wherein the inorganic base is selected from sodium bicarbonate, potassium carbonate, and potassium bicarbonate.
19. The process of claim 18, wherein the inorganic base is sodium bicarbonate.
20. A process for the preparation of oxazolidinone compounds of Formula Id
Figure imgf000013_0001
Formula Id comprising the steps of: a. reacting a compound of Formula I
Figure imgf000013_0002
Formula I with butyl lithium and glycidyl butyrate to form a compound of Formula la,
Figure imgf000014_0001
Formula la b. reacting the compound of Formula la with methane sulphonyl chloride, ammonium hydroxide and an acetyl halide of Formula CH3CO-hal, wherein hal is Br, CI or I, to form a compound of Formula lb,
Figure imgf000014_0002
Formula lb c. deprotecting the compound of Formula lb to form a compound of Formula Ic, and
Figure imgf000014_0003
, Formula Ic d. reacting the compound of Formula ic with R-T-(W)o-ι-R12 to form the compound of Formula Id, wherein T is a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring has at least one heteroatom selected from oxygen, nitrogen and sulfur, and T is further substituted by a group represented by R, wherein R is H, CHO, (Ci-QO-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(R6R7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-OR10, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (Cι-C12)-alkyl substituted with one or more of F, CI, Br, I, OR or SRf, wherein R5 is H, optionally substituted (Cι-C12)-alkyl, (C3-C12)-cycloall yl, aryl, heteroaryl, (Cι-C6)-alkoxy, or (Cι-C6)-alkyl substituted with one or more ofF, Cl, Br, I or OH; R6 and R7 is independently selected from H, optionally substituted (C1- 2)- alkyl, (C3-C12)-cycloalkyl, or (Cι-C6)-alkoxy; R8 and R9 is independently selected from H, (C1-C6)-alkyl, F, CI, Br, (C1.-C12)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R ) wherein R5, Rό and R7 is the same as defined earlier, R10 is H, optionally substituted (C1-C12)-alkyl, (C3-C12)-cycloalkyl, (C1-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; and W is CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(RU)CH2-, -CH2(Rn)N-, CH(Rι 1), S, CH2(CO), NH, wherein Rπ is optionally substituted (C1-C12)-alkyl, (C3-Ci2)-cycloalkyl, (C\- C6)-alkoxy, (Cι-C6)-alkyl, aryl or heteroaryl; and R12 is a leaving group.
21. The process of claim 20, wherein the leaving group is fluoro, chloro, bromo, SCH3, -SO2CH3, -SO2CF3 or OC6H5.
22. The process of claim 20, wherein the compound of Formula I is prepared by a process comprising the steps of: a. condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro- 4-nitropheyl)-piperazine of Formula II,
Figure imgf000015_0001
Formula II b. contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2-fluoro-4-nitrophenyl)-piperazine- 1-carboxylic acid butyl ester of Formula III,
Figure imgf000015_0002
c. reducing the compound of Formula III to form 4-(4-amino-2-fiuorophenyl)- piperazin-l-carboxylic acid tert-butyl ester of Formula IN, and
Figure imgf000016_0001
Formula TV d. reacting the compound of Formula TV with benzylchloroformate to form a compound 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazin-l-carboxylic acid tert butyl ester of Formula I.
Figure imgf000016_0002
Formula I 23. A compound prepared by a process comprising the steps of: condensing piperazine with l,2-difluoro-4-nitrobenzene to form a 4-(2-fluoro-4- nitropheyl)-piperazine of Formula II,
Figure imgf000016_0003
Formula II contacting the compound of Formula II with di-tert-butyl carboxylic anhydride to form 4-(2- fluoro-4-nitrophenyl)-piperazine- 1 -carboxylic acid butyl ester of Formula III,
Figure imgf000016_0004
Formula III reducing the compound of Formula III to form 4-(4-amino-2-fluorophenyl)-piperazin- 1 - carboxylic acid tert-butyl ester of Formula IN,
Figure imgf000017_0001
Formula IN and reacting the compound of Formula TV with benzylchloroformate. 24. A compound prepared by a process comprising the steps of: a. reacting a compound of Formula I
Figure imgf000017_0002
Formula I with butyl lithium and glycidyl butyrate to form a compound of Formula la,
Figure imgf000017_0003
Formula la b. reacting the compound of Formula la with methane sulphonyl chloride, ammonium hydroxide and an acetyl halide of Formula CH3CO-hal, wherein hal is Br, CI or I, to form a compound of Formula lb,
Figure imgf000017_0004
Formula lb deprotecting the compound of Formula lb to form a compound of Formula Ic, and
Figure imgf000017_0005
Formula Ic d. reacting the compound ofFormula lc with R-T-(W)0-ι-Ri2, wherein T is a five- to seven-membered heterocyclic ring, aryl or substituted aryl, bound to the piperazinyl ring via linker W, wherein the heterocyclic ring has at least one heteroatom selected from oxygen, nitrogen and sulfur, and T is further substituted by a group represented by R, wherein R is H, CHO, (C1-C6)-alkyl, F, CI, Br, I, -CN, COR5, COOR5, N(R6R7), CON(R6R7), CH2NO2, NO2, CH2R8, CHR9, -CH=N-OR10, -C=CH-R5, NHCOC(R8R9), NHCOOR10, CH(OAc)2, OR5, SR5, -C(R9)NO2, (C1-C12)-alkyl substituted with one or more of F, CI, Br, I, OR4 or SR4, wherein R5 is H, optionally substituted
Figure imgf000018_0001
(C3-Ci2)-cycloalkyl, aryl, heteroaryl, (C1-C6)-alkoxy, or ( -C^-alkyl substituted with one or more ofF, Cl, Br, I or OH; R6 and R7 is independently selected from H, optionally substituted ( -C12)- alkyl, (C3-C12)-cycloalkyl, or (C1-C6)-alkoxy; R8 and R9 is independently selected from H, (Cι-C6)-alkyl, F, CI, Br, ( -Cπ)- alkyl substituted with one or more of F, CI, Br, I, OR5, SR5, N(R6R7) wherein R5, R6 and R is the same as defined earlier, R10 is H, optionally substituted (Cι-Cι2)-alkyl, (C3-Cι2)-cycloalkyl, (Cι-C6)-alkoxy, (Cι-C6)-alkyl, aryl, or heteroaryl; and W is CH2, CO, -CH2 NH-, -NHCH2-, -CH2NHCH2-, -CH2-N(RU)CH2-, -CH2(Rπ)N-, CH(R, 1), S, CH2(CO), NH, wherein Rπ is optionally substituted (Cι-C12)-alkyl, (C3-Ci2)-cycloalkyl, (Ci- C6)-alkoxy, (C1-C6)-alkyl, aryl or heteroaryl; and R12 is a leaving group.
PCT/IB2004/003829 2003-11-28 2004-11-23 An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby WO2005051933A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IN1499DE2003 2003-11-28
IN1499/DEL/2003 2003-11-28

Publications (1)

Publication Number Publication Date
WO2005051933A1 true WO2005051933A1 (en) 2005-06-09

Family

ID=34631117

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2004/003829 WO2005051933A1 (en) 2003-11-28 2004-11-23 An improved process for the synthesis of 4-(4-benzyloxy-carbonylamino-2-fluorophenyl)-piperazine-1-carboxylic acid tert-butyl ester, a key intermediate for oxazolidinone antimicrobials and compounds prepared thereby

Country Status (1)

Country Link
WO (1) WO2005051933A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
US20110111058A1 (en) * 2009-11-06 2011-05-12 Robert Shalwitz Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US8426389B2 (en) 2009-02-03 2013-04-23 Trius Therapeutics, Inc. Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US9163043B2 (en) 2003-12-18 2015-10-20 Dong-A St Co., Ltd. Oxazolidinone derivatives

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023384A1 (en) * 1992-05-08 1993-11-25 The Upjohn Company Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
WO1997030981A1 (en) * 1996-02-26 1997-08-28 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
WO1998001447A1 (en) * 1996-07-06 1998-01-15 Zeneca Limited Pyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials
WO2002006278A1 (en) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2002048139A2 (en) * 2000-12-15 2002-06-20 Pharmacia & Upjohn Company Oxazolidinone photoaffinity probes
WO2003002560A1 (en) * 2001-06-27 2003-01-09 Laboratorios Vita, S.A. New derivatives of oxazolidinones as antibacterial agents
WO2003007870A2 (en) * 2001-07-16 2003-01-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2004018439A1 (en) * 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd Novel antibacterial agents

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023384A1 (en) * 1992-05-08 1993-11-25 The Upjohn Company Oxazolidinones containing a substituted diazine moiety and their use as antimicrobials
WO1997030981A1 (en) * 1996-02-26 1997-08-28 Pharmacia & Upjohn Company Azolyl piperazinyl phenyl oxazolidinone antimicrobials
WO1998001447A1 (en) * 1996-07-06 1998-01-15 Zeneca Limited Pyridyl-piperazinyl-phenyl-oxazolidinone derivatives and their use as antibacterials
WO2002006278A1 (en) * 2000-07-17 2002-01-24 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2002048139A2 (en) * 2000-12-15 2002-06-20 Pharmacia & Upjohn Company Oxazolidinone photoaffinity probes
WO2003002560A1 (en) * 2001-06-27 2003-01-09 Laboratorios Vita, S.A. New derivatives of oxazolidinones as antibacterial agents
WO2003007870A2 (en) * 2001-07-16 2003-01-30 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2004018439A1 (en) * 2002-08-22 2004-03-04 Orchid Chemicals & Pharmaceuticals Ltd Novel antibacterial agents

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DU YU ET AL: "Synthesis and antibacterial activity of linezolid analogUES" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 12, 2002, pages 857-859, XP002245432 ISSN: 0960-894X *
IN HWA CHUNG ET AL: "SYNTHESIS AND IN VITRO ANTIBACTERIAL ACTIVITY OF QUATERNARY AMMONIUM CEPHALOSPORIN DERIVATIVES BEARING OXAZOLIDINONE MOIETY" ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY, PUSAN, KR, vol. 22, no. 6, 1999, pages 579-584, XP001037701 ISSN: 0253-6269 *
PAE A N ET AL: "3D QSAR studies on new oxazolidinone antibacterial agents by comparative molecular field analysis" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 18, 20 September 1999 (1999-09-20), pages 2685-2690, XP004179952 ISSN: 0960-894X *
PAE A N ET AL: "Synthesis and In Vitro Activity of new Oxazolidinone Antibacterial Agents Having Substituted Isoxazoles" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, 1999, pages 2679-2684, XP002301080 ISSN: 0960-894X *
TUCKER J A ET AL: "PIPERAZINYL OXAZOLIDINONE ANTIBACTERIAL AGENTS CONTAINING A PYRIDINE, DIAZENE, OR TRIAZENE HETEROAROMATIC RING" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 19, 1998, pages 3727-3735, XP001203467 ISSN: 0022-2623 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9163043B2 (en) 2003-12-18 2015-10-20 Dong-A St Co., Ltd. Oxazolidinone derivatives
EP2757104A1 (en) * 2008-10-10 2014-07-23 Trius Therapeutics Compounds used in the synthesis of oxazolidinones
WO2010042887A3 (en) * 2008-10-10 2010-06-24 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
JP2012505252A (en) * 2008-10-10 2012-03-01 トリウス セラピューティクス Methods of preparing oxazolidinones and compositions containing them
WO2010042887A2 (en) * 2008-10-10 2010-04-15 Trius Therapeutics Methods for preparing oxazolidinones and compositions containing them
RU2659792C1 (en) * 2008-10-10 2018-07-04 Мерк Шарп Энд Домэ Корп. Oxazolidinones and the method of their cleaning
US8604209B2 (en) 2008-10-10 2013-12-10 Trius Therapeutics, Inc. Methods for preparing oxazolidinones and compositions containing them
US9328087B2 (en) 2008-10-10 2016-05-03 Merck Sharp & Dohme Corp. Methods for preparing oxazolidinones and compositions containing them
US10065947B1 (en) 2009-02-03 2018-09-04 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US9988406B2 (en) 2009-02-03 2018-06-05 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8426389B2 (en) 2009-02-03 2013-04-23 Trius Therapeutics, Inc. Crystalline form of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US10442829B2 (en) 2009-02-03 2019-10-15 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US9624250B2 (en) 2009-02-03 2017-04-18 Merck Sharp & Dohme Corp. Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate
US8580767B2 (en) 2009-05-28 2013-11-12 Trius Therapeutics, Inc. Oxazolidinone containing dimer compounds, compositions and methods to make and use
US20150157617A1 (en) * 2009-11-06 2015-06-11 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US9540326B2 (en) 2009-11-06 2017-01-10 Aerpio Therapeutics, Inc. Prolyl hydroxylase inhibitors
US9278930B2 (en) 2009-11-06 2016-03-08 Aerpio Therapeutics, Inc. Methods for increasing the stabilization of hypoxia inducible factor-α
US8999971B2 (en) 2009-11-06 2015-04-07 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US8778412B2 (en) * 2009-11-06 2014-07-15 Aerpio Therapeutics Inc. Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US20110111058A1 (en) * 2009-11-06 2011-05-12 Robert Shalwitz Methods for increasing the stabilization of hypoxia inducible factor-1 alpha
US10562854B2 (en) 2009-11-06 2020-02-18 Aerpio Therapeutics, Inc. Prolyl hydroxylase inhibitors

Similar Documents

Publication Publication Date Title
US8168784B2 (en) Processes to make apoptosis promoters
US7863460B2 (en) Process for producing 1-substituted-3-fluoroalkylpyrazole-4-carboxylate
CA2886482C (en) Processes for the synthesis of 5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine and its intermediates
Xiong et al. Remote amide-directed palladium-catalyzed benzylic C–H amination with N-fluorobenzenesulfonimide
Batey et al. An efficient new protocol for the formation of unsymmetrical tri-and tetrasubstituted ureas
WO2013042695A1 (en) Metal porphyrin complex, method for producing same, carbon dioxide immobilization catalyst comprising same, and method for producing cyclic carbonic acid ester.
US5712418A (en) Synthesis and use of amino acid fluorides as peptide coupling reagents
Orgueira et al. Regioselective synthesis of [1, 2, 3]-triazoles catalyzed by Cu (I) generated in situ from Cu (0) nanosize activated powder and amine hydrochloride salts
US5618966A (en) Method forming protease inhibitor synthetic intermediates
SU613722A3 (en) Method of obtaining substituted pyrazoles
Zhang et al. Copper-catalyzed aerobic oxidative synthesis of α-ketoamides from methyl ketones, amines and NIS at room temperature
TWI419863B (en) Process for preparing 2-dihaloacyl-3-aminoacrylic acid derivatives
RU2256657C2 (en) Method for carbamoylation of alcohols
EA010633B1 (en) Novel benzaldoximes, method for preparing thereof and use
HU0203851A2 (en) Method for production of a triazolinethione derivative
TW200530189A (en) Preparation of fluoromethyl-substituted heterocycles
KR20160071179A (en) Polymer resin-anchored ionic liquid catalyst and preparing method of n,n'-substituted urea using the same
JP2006188470A (en) Indoline derivative and method for producing the same
KR20060037417A (en) Process for production of cis-4-fluoro-l-proline derivatives
AU2006276072A1 (en) Process for synthesizing a substituted pyrazole
JP2004517871A (en) Method for producing 2- (2-hydroxyphenyl) -2H-benzotriazole
Claus et al. N-aryl sulfimides
KR20040099279A (en) Method for preparing benzisoxazole methane sulfonyl chloride and its amidation to form zonisamide
Newcomb et al. Facile production and cyclizations of amidyl radicals
MXPA03008647A (en) Process for the industrial synthesis of tetraesters of 5-[bis (carboxymethyl) amino]-3 -carboxymethyl -4-cyano -2-thiophenecarboxylic acid, and application to the synthesis of bivalent salts of ranelic acid and their hydrates.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct app. not ent. europ. phase